Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | USP5 | P45974 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075730 | 0.91 | NPC1 (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2PDE4A | |
| SCHEMBL19083825 | 0.84 | POLB (0.52) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL19083819 | 0.83 | L3MBTL1 (0.68) | L3MBTL1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL19083718 | 0.79 | TAS1R3 (0.51) | ALDH1A1 | |
| SCHEMBL19075712 | 0.76 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL19075738 | 0.76 | POLB (0.52) | RAB9APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19075740 | 0.76 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL20697599 | 0.76 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL19083823 | 0.76 | L3MBTL1 (0.55) | L3MBTL1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL19075747 | 0.75 | PDE4A (0.61) | RAB9ASMN1; SMN2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | L3MBTL1 3827/4885NPC1 1736/4885RAB9A 915/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | L3MBTL1 3827/4885NPC1 1736/4885RAB9A 915/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | L3MBTL1 3827/4885NPC1 1736/4885RAB9A 915/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | L3MBTL1 3827/4885NPC1 1736/4885RAB9A 915/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | L3MBTL1 3827/4885NPC1 1736/4885RAB9A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.